IONS
IONIS PHARMACEUTICALS INC
$73.54
-1.26%
$12.2B
No data for this timeframe.
Vol
Market Cap$12.2B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (82%)
Inst. Holders10 funds
Inst. Value$3.9B
Inst. Activity2 buys / 1 sells
Insider Activity0B / 19S
Insider Net $-$29.5M
SEC Reports6
Recent Activity
Oct 26, 2026
fda_pdufa
PDUFA: IONS — bepirovirsen in chronic hepatitis B (CHB) — 2026-10-26
FDA target action date 2026-10-26 for IONS (IONIS PHARMACEUTICALS INC). Drug: bepirovirsen. Indicati
Jun 8, 2026
SEC
Ionis Pharmaceuticals appointed Ludwig Hantson, Ph.D. to its Board of Directors effective June 4, 2026, and reported sha
8-K — Impact 3/10
Jun 4, 2026
Insider
HANTSON LUDWIG sold 10,753 shares
Director @ $0.00 ($0.00)
Jun 4, 2026
Insider
Reikes Peter N sold 10,753 shares
Director @ $0.00 ($0.00)
Jun 1, 2026
Insider
BERTHELSEN SPENCER R sold 8,000 shares
Director @ $0.00 ($0.00)
May 28, 2026
SEC
Ionis partner GSK reported positive Phase 3 data for bepirovirsen in chronic hepatitis B, showing a 19% functional cure
8-K — Impact 7/10
May 6, 2026
SEC
Two IONS directors sold approximately $5.1M in stock, which is trivial relative to the company's $12.4B market cap (0.04
CLUSTER — Impact 3/10
Inst.
TWO SIGMA INVESTMENTS, LP — ADD
2,658,646 shares ($210.3M)
Price Targets
$100.92
+35.3% upside
Strong Buy
Current $74.58
Low $47.00
Median $105.00
High $130.00
25 analysts
$47.00
$130.00
Analyst Ratings
10Strong Buy
17Buy
6Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 1, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 19, 2026 | Citigroup | INITIATE | Buy |
| Apr 30, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
| Apr 30, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| Apr 30, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.87 | $-1.03 — $-0.64 | -203% YoY | 7 |
| Next Q | $-0.81 | $-0.93 — $-0.61 | -32% YoY | 7 |
| Current FY | $-2.56 | $-2.79 — $-2.04 | -66% YoY | 9 |
| Next FY | $-0.62 | $-2.21 — $0.26 | 76% YoY | 10 |
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $1.9B | — |
| VANGUARD GROUP INC | $1.3B | — |
| TWO SIGMA INVESTMENTS, LP | $210.3M | ADD |
| Tweedy, Browne Co LLC | $195.0M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $122.0M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | HANTSON LUDWIG | A | $0.00 |
| Jun 4, 2026 | Reikes Peter | A | $0.00 |
| Jun 1, 2026 | BERTHELSEN SPENCER | M | $0.00 |
| Jun 1, 2026 | BERTHELSEN SPENCER | SELL | $605.4K |
| Jun 1, 2026 | BERTHELSEN SPENCER | M | $195.4K |
10 institutional holders with $3.9B total value (49,805,274 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, TWO. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 24,072,101 | $1.9B | 48.3% | — |
| 2 | VANGUARD GROUP INC | 16,440,459 | $1.3B | 33.0% | — |
| 3 | TWO SIGMA INVESTMENTS, LP | 2,658,646 | $210.3M | 5.3% | ADD +68.7% |
| 4 | Tweedy, Browne Co LLC | 2,464,930 | $195.0M | 4.9% | — |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,541,841 | $122.0M | 3.1% | NEW |
| 6 | MORGAN STANLEY | 1,019,906 | $80.7M | 2.0% | ADD +29.4% |
| 7 | BANK OF AMERICA CORP /DE/ | 783,579 | $62.0M | 1.6% | ADD +29.8% |
| 8 | NORGES BANK | 320,160 | $25.3M | 0.6% | NEW |
| 9 | WELLS FARGO & COMPANY/MN | 280,045 | $22.2M | 0.6% | ADD +35.9% |
| 10 | RENAISSANCE TECHNOLOGIES LLC | 223,607 | $17.7M | 0.4% | TRIM -54.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | ADD | 1,575,943 | 2,658,646 | +68.7% | $210.3M | 2025-Q4 |
| NORGES BANK | NEW | — | 320,160 | — | $25.3M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 486,714 | 223,607 | -54.1% | $17.7M | 2025-Q4 |
| UBS Group AG | TRIM | 1,529,323 | 1,046,990 | -31.5% | $68.5M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 270,714 | 486,714 | +79.8% | $31.8M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 209,857 | 285,293 | +35.9% | $18.7M | 2025-Q3 |
| NORGES BANK | EXIT | 450,254 | 0 | -100.0% | $0.00 | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 767,432 | 995,890 | +29.8% | $39.3M | 2025-Q2 |
| NORGES BANK | NEW | — | 450,254 | — | $17.8M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 153,514 | 270,714 | +76.3% | $10.7M | 2025-Q2 |
| CITADEL ADVISORS LLC | ADD | 2,263,416 | 3,615,962 | +59.8% | $109.1M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | ADD | 921,439 | 1,685,853 | +83.0% | $50.9M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 205,514 | 153,514 | -25.3% | $4.6M | 2025-Q1 |
| NORGES BANK | EXIT | 1,714,762 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 497,651 | 2,263,416 | +354.8% | $79.1M | 2024-Q4 |
| UBS Group AG | DOUBLED | 167,880 | 1,917,608 | +1042.2% | $67.0M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 1,443,020 | — | $57.8M | 2024-Q3 |
| MORGAN STANLEY | ADD | 1,012,805 | 1,310,451 | +29.4% | $52.5M | 2024-Q3 |
14 unique insiders with 19 transactions. Net insider value: -$29.5M ($0.00 bought, $29.5M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | HANTSON LUDWIG | Director | A | 10,753 | $0.00 | $0.00 |
| Jun 4, 2026 | Reikes Peter N | Director | A | 10,753 | $0.00 | $0.00 |
| Jun 1, 2026 | BERTHELSEN SPENCER R | Director | M | 8,000 | $0.00 | $0.00 |
| Jun 1, 2026 | BERTHELSEN SPENCER R | Director | SELL | 8,000 | $75.67 | $605.4K |
| Jun 1, 2026 | BERTHELSEN SPENCER R | Director | M | 8,000 | $24.42 | $195.4K |
| May 14, 2026 | Monia Brett P | Chief Executive Officer | M | 3,220 | $32.60 | $105.0K |
| May 14, 2026 | Monia Brett P | Chief Executive Officer | M | 3,220 | $0.00 | $0.00 |
| May 14, 2026 | Monia Brett P | Chief Executive Officer | SELL | 3,220 | $78.68 | $253.3K |
| May 13, 2026 | Monia Brett P | Chief Executive Officer | M | 1,316 | $32.60 | $42.9K |
| May 13, 2026 | Monia Brett P | Chief Executive Officer | SELL | 1,316 | $78.01 | $102.7K |
| May 13, 2026 | Monia Brett P | Chief Executive Officer | M | 1,316 | $0.00 | $0.00 |
| May 4, 2026 | LOSCALZO JOSEPH | Director | M | 10,968 | $0.00 | $0.00 |
| May 4, 2026 | LOSCALZO JOSEPH | Director | SELL | 59,508 | $74.90 | $4.5M |
| May 4, 2026 | LOSCALZO JOSEPH | Director | M | 10,968 | $38.06 | $417.4K |
| May 1, 2026 | KLEIN JOSEPH III | Director | M | 10,111 | $47.11 | $476.3K |
| May 1, 2026 | KLEIN JOSEPH III | Director | M | 10,111 | $0.00 | $0.00 |
| May 1, 2026 | KLEIN JOSEPH III | Director | SELL | 8,680 | $73.35 | $636.7K |
| Apr 28, 2026 | Baroldi Joseph | EVP, Chief Business Officer | SELL | 1,626 | $71.79 | $116.7K |
| Apr 16, 2026 | Baroldi Joseph | EVP, Chief Business Officer | SELL | 5,619 | $74.56 | $419.0K |
| Apr 16, 2026 | Birchler Brian | EVP, Corp and Development Ops | SELL | 973 | $75.04 | $73.0K |
| Apr 16, 2026 | Jenne Kyle | EVP, Chf GL Pdt Str Ofcr | SELL | 4,902 | $75.17 | $368.5K |
| Apr 15, 2026 | Baroldi Joseph | EVP, Chief Business Officer | M | 10,837 | $0.00 | $0.00 |
| Apr 15, 2026 | Jenne Kyle | EVP, Chf GL Pdt Str Ofcr | M | 12,226 | $0.00 | $0.00 |
| Apr 15, 2026 | Baroldi Joseph | EVP, Chief Business Officer | M | 10,837 | $0.00 | $0.00 |
| Apr 15, 2026 | Birchler Brian | EVP, Corp and Development Ops | M | 1,875 | $0.00 | $0.00 |
| Apr 15, 2026 | Birchler Brian | EVP, Corp and Development Ops | M | 1,875 | $0.00 | $0.00 |
| Apr 15, 2026 | PARSHALL B LYNNE | Director | SELL | 4,466 | $76.19 | $340.3K |
| Apr 15, 2026 | Jenne Kyle | EVP, Chf GL Pdt Str Ofcr | M | 12,226 | $0.00 | $0.00 |
| Apr 2, 2026 | Devers Shannon L. | EVP, Chief Human Resources Ofc | SELL | 6,193 | $74.05 | $458.6K |
| Apr 1, 2026 | KLEIN JOSEPH III | Director | M | 12,000 | $38.06 | $456.7K |
| Apr 1, 2026 | KLEIN JOSEPH III | Director | SELL | 20,105 | $75.50 | $1.5M |
| Apr 1, 2026 | KLEIN JOSEPH III | Director | M | 12,000 | $0.00 | $0.00 |
| Mar 19, 2026 | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | SELL | 5,812 | $70.97 | $412.5K |
| Mar 17, 2026 | HOUGEN ELIZABETH L | EVP, Finance & CFO | SELL | 10,172 | $73.21 | $744.7K |
| Mar 16, 2026 | HOUGEN ELIZABETH L | EVP, Finance & CFO | M | 33,118 | $0.00 | $0.00 |
| Mar 16, 2026 | HOUGEN ELIZABETH L | EVP, Finance & CFO | SELL | 205,608 | $72.38 | $14.9M |
| Mar 16, 2026 | HOUGEN ELIZABETH L | EVP, Finance & CFO | M | 60,299 | $60.89 | $3.7M |
| Mar 10, 2026 | Jenne Kyle | EVP, Chf GL Pdt Str Ofcr | M | 4,675 | $0.00 | $0.00 |
| Mar 10, 2026 | Jenne Kyle | EVP, Chf GL Pdt Str Ofcr | SELL | 21,191 | $75.50 | $1.6M |
| Mar 10, 2026 | Jenne Kyle | EVP, Chf GL Pdt Str Ofcr | M | 32,602 | $46.10 | $1.5M |
| Mar 10, 2026 | Monia Brett P | Chief Executive Officer | M | 34,103 | $0.00 | $0.00 |
| Mar 10, 2026 | Monia Brett P | Chief Executive Officer | M | 34,103 | $60.89 | $2.1M |
| Mar 10, 2026 | Monia Brett P | Chief Executive Officer | SELL | 16,512 | $75.47 | $1.2M |
| Mar 9, 2026 | Monia Brett P | Chief Executive Officer | M | 40,822 | $0.00 | $0.00 |
| Mar 9, 2026 | Monia Brett P | Chief Executive Officer | SELL | 7,382 | $74.11 | $547.1K |
| Mar 9, 2026 | Monia Brett P | Chief Executive Officer | M | 40,822 | $60.89 | $2.5M |
| Mar 9, 2026 | O'NEIL PATRICK R. | EVP CLO & General Counsel | SELL | 10,148 | $75.25 | $763.7K |
| Mar 4, 2026 | LOSCALZO JOSEPH | Director | M | 200 | $38.06 | $7.6K |
| Mar 4, 2026 | LOSCALZO JOSEPH | Director | M | 200 | $0.00 | $0.00 |
| Mar 4, 2026 | Baroldi Joseph | EVP, Chief Business Officer | M | 238 | $56.78 | $13.5K |
6 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 1 mixed, 3 neutral. Avg impact: 5.0/10.
NEUTRAL
8-K
3/10
Ionis Pharmaceuticals appointed Ludwig Hantson, Ph.D. to its Board of Directors effective June 4, 20
Jun 8, 2026
BULLISH
8-K
7/10
Ionis partner GSK reported positive Phase 3 data for bepirovirsen in chronic hepatitis B, showing a
May 28, 2026
NEUTRAL
CLUSTER
3/10
Two IONS directors sold approximately $5.1M in stock, which is trivial relative to the company's $12
May 6, 2026
BULLISH
8-K
8/10
Ionis Pharmaceuticals announced positive results from the pivotal study of zilganersen in Alexander
Apr 21, 2026
NEUTRAL
CLUSTER
3/10
Two Ionis Pharmaceuticals executives, including the Chief Business Officer and EVP of Corporate and
Apr 17, 2026
MIXED
8-K
6/10
Ionis Pharmaceuticals reported full-year 2025 revenue of $944 million, exceeding guidance due to str
Feb 25, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (82% buy). Based on 33 analysts: 10 strong buy, 17 buy, 6 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$100.92 mean target
+35.3% upside
Strong Buy (1.73)
$47.00 Low
$130.00 High
| Metric | Value |
|---|---|
| Current Price | $74.58 |
| Target Low | $47.00 |
| Target Mean | $100.92 |
| Target Median | $105.00 |
| Target High | $130.00 |
| # Analysts | 25 |
| Recommendation | Strong Buy (1.73) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.87 | $-1.03 | $-0.64 | -203.3% | +0.0% | 4↑ 2↓ | $0.2B | -58.0% | 7 |
| Next Q 2026-09-30 |
$-0.81 | $-0.93 | $-0.61 | -32.2% | +0.0% | 5↑ 0↓ | $0.2B | 29.8% | 7 |
| Current FY 2026-12-31 |
$-2.56 | $-2.79 | $-2.04 | -65.7% | -0.0% | 7↑ 0↓ | $0.9B | -5.7% | 9 |
| Next FY 2027-12-31 |
$-0.62 | $-2.21 | $0.26 | 75.7% | -0.3% | 4↑ 3↓ | $1.5B | 66.8% | 10 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.874 | |
| 7d ago | $-0.874 | |
| 30d ago | $-0.874 | |
| 60d ago | $-0.947 | +0.072 |
| 90d ago | $-0.927 | +0.052 |
13 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 1, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 19, 2026 | Citigroup | INITIATE | — | Buy |
| Apr 30, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Apr 30, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Apr 30, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 23, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| Apr 21, 2026 | Canaccord Genuity | INITIATE | — | Buy |
| Apr 21, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Apr 9, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Mar 26, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Mar 25, 2026 | Needham | MAINTAIN | Buy | Buy |
| Mar 25, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 3, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Feb 27, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Feb 26, 2026 | Stifel | MAINTAIN | Hold | Hold |
| Feb 26, 2026 | Needham | MAINTAIN | Buy | Buy |
| Feb 6, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Jan 5, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Dec 17, 2025 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Dec 15, 2025 | Leerink Partners | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 10 | 17 | 6 | 0 | 0 | 82% | |
| May 1, 2026 | 9 | 16 | 6 | 0 | 0 | 81% | |
| Apr 1, 2026 | 9 | 13 | 7 | 0 | 0 | 76% | |
| Mar 1, 2026 | 9 | 13 | 7 | 0 | 0 | 76% | |
| Feb 1, 2026 | 9 | 13 | 7 | 0 | 0 | 76% | |
| Jan 1, 2026 | 9 | 13 | 7 | 0 | 0 | 76% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Oct 26, 2026
fda_pdufa
PDUFA: IONS — bepirovirsen in chronic hepatitis B (CHB) — 2026-10-26
FDA target action date 2026-10-26 for IONS (IONIS PHARMACEUTICALS INC). Drug: bepirovirsen. Indication: chronic hepatitis B (CHB). NDA accepted for Pr
Sep 22, 2026
fda_pdufa
PDUFA: IONS — zilganersen in Alexander disease — 2026-09-22
FDA target action date 2026-09-22 for IONS (IONIS PHARMACEUTICALS INC). Drug: zilganersen. Indication: Alexander disease. PDUFA action date set for zi
Jun 30, 2026
fda_pdufa
PDUFA: IONS — olezarsen in severe hypertriglyceridemia (sHTG) — 2026-06-30
FDA target action date 2026-06-30 for IONS (IONIS PHARMACEUTICALS INC). Drug: olezarsen. Indication: severe hypertriglyceridemia (sHTG). sNDA accepted
Jun 9, 2026
short_volume
Short Volume: IONS — 57.0% short (0.3M / 0.6M)
Short: 316,982 | Exempt: 73 | TRF Vol: 556,432 | Short Ratio: 57.0% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: IONS — 66.5% short (0.5M / 0.8M)
Short: 533,630 | Exempt: 31 | TRF Vol: 802,247 | Short Ratio: 66.5% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: IONS — 63.0% short (0.3M / 0.5M)
Short: 318,576 | Exempt: 4,545 | TRF Vol: 505,974 | Short Ratio: 63.0% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: IONS — 76.6% short (0.6M / 0.7M)
Short: 563,932 | Exempt: 615 | TRF Vol: 735,804 | Short Ratio: 76.6% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: IONS — 58.1% short (0.4M / 0.6M)
Short: 362,241 | Exempt: 14 | TRF Vol: 623,981 | Short Ratio: 58.1% | Off-exchange volume (dark pool + OTC)
May 21, 2026
short_volume
Short Volume: IONS — 76.9% short (0.9M / 1.1M)
Short: 874,404 | Exempt: 1,202 | TRF Vol: 1,137,660 | Short Ratio: 76.9% | Off-exchange volume (dark pool + OTC)
May 20, 2026
short_volume
Short Volume: IONS — 73.4% short (0.6M / 0.8M)
Short: 620,303 | Exempt: 940 | TRF Vol: 844,909 | Short Ratio: 73.4% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: IONS — 56.6% short (0.3M / 0.6M)
Short: 320,655 | Exempt: 398 | TRF Vol: 566,292 | Short Ratio: 56.6% | Off-exchange volume (dark pool + OTC)
May 18, 2026
dark_pool
Dark Pool: IONS — 3.4M shares, 49,283 trades
Week starting 2026-05-18. Total ATS volume: 3,442,223 shares across 49,283 trades.
May 15, 2026
short_volume
Short Volume: IONS — 67.4% short (0.5M / 0.7M)
Short: 490,283 | Exempt: 58 | TRF Vol: 727,164 | Short Ratio: 67.4% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: IONS — 58.3% short (0.4M / 0.7M)
Short: 423,666 | Exempt: 250 | TRF Vol: 726,983 | Short Ratio: 58.3% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_volume
Short Volume: IONS — 58.2% short (0.3M / 0.6M)
Short: 328,229 | Exempt: 526 | TRF Vol: 563,607 | Short Ratio: 58.2% | Off-exchange volume (dark pool + OTC)
May 8, 2026
Clinical Trial
An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema
Phase Phase 2 — COMPLETED
Apr 23, 2026
Clinical Trial
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia
Phase Phase 2 — COMPLETED
Apr 2, 2026
Clinical Trial
FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)
Phase Phase 3 — ACTIVE_NOT_RECRUITING